Regression of human metastatic renal cell carcinoma after vaccination with tumor cell–dendritic cell hybrids

By A. Kugler, G. Stuhler, P. Walden, G. Zöller, A. Zobywalski, P. Brossart, U. Trefzer, S. Ullrich, C. Müller, V. Becker and 5 more. Nature Medicine, 2000

684 citations recorded by the source corpus.

Subfields: Immunology, Oncology

View Paper: https://www.semanticscholar.org/paper/64746a28042b4a3dcaa34382e73814cf6ec245b4

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

1. G. Hudes
2. W. Stadler
3. M. Atkins
4. J. Boni
5. J. Dutcher
6. M. Hidalgo
7. Kensho Suzuki
8. T. Logan

Citations in the corpus

• Proliferative activity of intratumoral CD8(+) T-lymphocytes as a prognostic factor in human renal cell carcinoma: clinicopathologic demonstration of antitumor immunity. (2001, background): “Despite these obstacles, renal cell carcinoma has been known for the effectiveness of lymphokineactivated killer and cytokine therapies (5–7) and therapy using tumor cell-dendritic cell hybrids (8).”
• Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma. (2004, background): “Various treatment approaches have been investigated in this patient population, including thalidomide [42-44], anti–VEGF antibody [41,45], dendritic cell vaccines [46,47], and nonmyeloablative allogeneic transplantation [48].”